HOME > TOP STORIES

TOP STORIES

BUSINESS Sanofi Files PD-1 Drug Cemiplimab for Cervical Cancer in Japan

March 22, 2022
BUSINESS Generic Makers, PMDA Exploring GMP Inspection Methods for Overseas Sites; Onsite Checks Not Possible for 2 Years

March 18, 2022
REGULATORY MHLW Panel to Discuss Pfizer COVID Booster for Ages 12-17

March 18, 2022
BUSINESS Aduhelm Deal Revised, Eisai Poised to Sharpen Focus on Lecanemab: CEO

March 17, 2022
COMMENTARY Drug Makers Guard against Price Adjustment Rate, Off-Year Revision Debates: Jiho Poll

March 16, 2022
BUSINESS Biogen/Eisai Alzheimer’s Pact Amended to Switch Aducanumab Collab to Royalty Scheme

March 16, 2022
ORGANIZATION API Import Costs from Europe Surging amid Russian Airspace Closures

March 15, 2022
ORGANIZATION List of 180 Needed Drugs Compiled in Europe-Led Drive to Support Ukraine

March 14, 2022
BUSINESS Moderna Accelerating Bivalent Vaccine Development for 4th COVID Shot: Japan Chief

March 14, 2022
BUSINESS Fujifilm Drops Avigan’s Japan PIII Trial for COVID-19

March 14, 2022
BUSINESS Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally

March 11, 2022
BUSINESS Chugai Won’t Challenge Edirol Substance Patent Ruling

March 11, 2022
REGULATORY Panel Confirms Backing for Alexion’s Bleeding Antidote after Data Integrity Issues

March 10, 2022
BUSINESS Japan Drug Makers Moving to Support War-Hit Ukraine

March 10, 2022
BUSINESS Double-Digit Slashes to Hit 44 Major Drugs in 2022 Price Revision: Top 5 Product Poll

March 9, 2022
REGULATORY MHLW Publishes Brand-by-Brand Supply Status for 130 APIs Subject to Its Restriction Lifting Request

March 9, 2022
ORGANIZATION Apply Only Market Price-Linked Rules in Next Off-Year Revision, No Hasty Debate for Adjustment Rate: JMA Official

March 8, 2022
BUSINESS SanBio’s Sakigake Cell Therapy Finally Filed in Japan for Traumatic Brain Injury

March 8, 2022
BUSINESS Eisai Suffers 9%-Plus Cut, Sumitomo Dainippon Over 8% in 2022 Drug Price Revision: Jiho Poll

March 7, 2022
REGULATORY Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision

March 4, 2022

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…